Gosset Ownership
Public
Employees
~30
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Aerovate Therapeutics General Information
The Phase 2b IMPAHCT trial for AV-101 failed to meet its primary endpoint for improvement in PAH compared to placebo for any of the studied doses. The drug also failed to show meaningful improvements in the secondary endpoint of change in six-minute walk distance. As a result, the Phase 3 and long-term extension arms were stopped, and the company announced a 78% workforce reduction in July 2024[10].
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Waltham, Massachusetts
United States
United States
Drug Pipeline
imatinib
Phase 2Key Partnerships
Aerovate Therapeutics Funding
No funding data available
To view Aerovate Therapeutics's complete valuation and funding history, request access »
Aerovate Therapeutics Financial Metrics
Market Cap
$77.7M
Enterprise Value
$-10034200